Clinical bottom line
Sleep quality and duration are increasingly recognized as important factors influencing glycemic control and overall diabetes management. Poor sleep, including insomnia and disrupted sleep patterns, is associated with worsened glycemic outcomes and increased diabetes-related distress in both type 1 and type 2 diabetes populations. Interventions such as cognitive behavioral therapy for insomnia (CBT-I) delivered remotely show promise in improving sleep and glycemic parameters. Incorporating sleep assessment and management into diabetes care may enhance metabolic control and patient quality of life.
What the evidence shows
Marhefková et al. (2025) compared sleep duration and timing in individuals with type 1 diabetes versus the general population, finding that diabetes is linked to altered sleep patterns that may contribute to metabolic dysregulation.
Jeon et al. (2026) used path analysis to demonstrate that sleep disturbances exacerbate diabetes-related distress, which in turn negatively impacts glycemic control, highlighting a bidirectional relationship.
Kirisri et al. (2025) conducted a randomized controlled trial showing that remotely delivered CBT-I significantly improved sleep quality and modestly reduced HbA1c in adults with type 2 diabetes, supporting behavioral interventions as feasible adjuncts.
Smyth et al. (2020) systematically reviewed clinical practice guidelines and identified consistent recommendations for routine sleep assessment in type 2 diabetes management, emphasizing its role in comprehensive care.
Botella-Serrano et al. (2022) evaluated adults with type 1 diabetes and found that poor sleep quality and short sleep duration were associated with higher glycemic variability, suggesting sleep as a modifiable factor in glucose stability.
Earlier studies, such as Priya et al. (2015), also reported correlations between reduced sleep duration and poorer glycemic control in type 2 diabetes, reinforcing the importance of sleep hygiene.
Caveats and uncertainty
Most studies are observational or small-scale interventional trials, limiting causal inference and generalizability.
Sleep disturbances in diabetes are multifactorial, influenced by neuropathy, nocturia, and psychological factors, complicating targeted interventions.
Long-term effects of sleep improvement on hard clinical outcomes such as microvascular complications remain underexplored.
Optimal screening tools and thresholds for clinically significant sleep disturbances in diabetes populations require standardization.
How this may change practice
Clinicians should incorporate routine screening for sleep quality and duration in diabetes care, using validated questionnaires or clinical interviews.
Behavioral interventions like CBT-I, including digital delivery formats, may be considered to improve sleep and glycemic outcomes, especially in patients reporting insomnia symptoms.
Addressing sleep disturbances may reduce diabetes-related distress and improve adherence to self-management.
Multidisciplinary collaboration with sleep specialists and mental health providers can optimize care for patients with complex sleep and metabolic issues.
Future guidelines may formalize sleep assessment as a standard component of diabetes management protocols.